Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease.

This study aimed to investigate the relationship between serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). A cross-sectional study was conducted using nationally representative samples from the Korea National Health and Nutrition Examination Survey 2010. Significant hepatic fibrosis was defined as Fibrosis-4 (FIB-4) index>1.3. Zinc level was measured using inductively coupled plasma mass spectrometry. Univariable and multivariable logistic regression analyses were performed to assess risk factors for significant hepatic fibrosis in patients with NAFLD. A total of 300 patients with NAFLD were analyzed in this study. The mean serum zinc level was 139.8±29.9 μg/dL. FIB-4 index was significantly increased as the serum zinc level decreased (Adjusted correlation coefficient = -0.177, p = 0.003). Significant liver fibrosis was observed in 62 patients (21%). The multivariable analysis showed that significant liver fibrosis in NAFLD was associated with diabetes mellitus (odds ratio [OR], 3.25; 95% confidence interval [CI], 1.71-6.19; p<0.001), male (OR, 2.59; 95% CI, 1.31-5.12; p = 0.006), and zinc level <140 μg/dL (OR, 2.14; 95% CI, 1.16-3.94; p = 0.015). There was an inverse relationship between serum zinc level and FIB-4 index in NAFLD. Low levels of serum zinc were an independent risk factor for significant hepatic fibrosis in NAFLD.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease, which is defined as intrahepatic triglyceride content of >5%. It has become widespread with the increasing prevalence of obesity and metabolic syndrome. The spectrum of NAFLD includes simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It also results in liver cancer [1]. NAFLD is a multifactorial disease with complex pathophysiology such as obesity, insulin resistance (IR), dyslipidemia, and metabolic syndrome [2]. Moreover, in many cases, the progression of NASH to cirrhosis remained indolent without specific symptoms until advanced liver disease.

Zinc (Zn) is an essential trace mineral element scavenging free radical oxygen species in human and plays a key factor in hepatic lipid metabolism [3]. Zn is an inhibitor of NADPH oxidase which plays an important role in the production of O2●− (known as reactive oxygen species from oxygen). Besides, the metallothionein, metal binding proteins produced by Zn is an excellent scavenger of ●OH. Zn is also competing with iron and copper which catalyze the production of ●OH from H2O2 by binding to the cell membrane [4]. Thus, Zn acts as a potent promoter of autophagy-mediated lipophagy in the liver, reducing lipid accumulation and stimulating lipolysis [5]. In patients with chronic viral hepatitis combined with/without HIV infection, lower Zn level was not only associated with severe liver fibrosis and cirrhosis-related complications such as variceal bleeding but also increased mitochondrial oxidative stress [6, 7]. In the aspect of alcoholic liver disease, the metallothionein which is an antioxidant produced by Zn showed a cytoprotective effect on the liver [8]. Several basic studies examined the role of Zn in NAFLD or NASH. NASH or cirrhosis may alter the process of trace mineral metabolism, and decreased Zn level was reversely associated with hepatic steatosis with a leptin receptor deficiency or dysregulation of a large number of genes in lipid metabolism [9, 10]. Moreover, oxidative stress related with the change in activity of antioxidant enzyme including Zn is a well-known important pathophysiological factor in NASH progression [11].

Thus, the basic studies showed that serum Zn level and NAFLD are closely related with each other in physiologic mechanism and disease progression. Recently, the relationship between Zinc and hepatic fibrosis was revealed in patients with biopsy-proven NAFLD [12]. However, liver biopsy is not widely used as a routine screening tool to detect or monitor fibrosis progression in NAFLD because of its invasiveness and the cost. The present study aimed to examine the role of Zn in patients with NAFLD using a nationally representative database in Korea. We investigated the effect of serum Zn level on hepatic fibrosis represented by simple and noninvasive blood-based biomarker in patients with NAFLD.

Methods

Study population

This cross-sectional study was conducted based on data from the Korea National Health and Nutritional Examination Survey (KNHANES). The KNHANES, a nationally representative survey, is performed by the Korea Centers for Disease Control and Prevention (KCDC). It is based on a complex, stratified, multistage, and probability cluster sampling of the noninstitutionalized population in Korea [13]. This survey consists of four parts: health interview survey, nutrition survey, health behavior survey, and health examination survey. The health interview and examination were performed by trained medical staffs and interviewers at the mobile examination center. The KNHANES has been periodically performed since 1998. This study was conducted using KNHANES 2010.

The target population of this survey was all noninstitutionalized Korean civilians aged >1 year. The survey was conducted with the sampling units based on sex, age, and geographic areas, which were determined according to the household registries of the Korean National Census Registry. Written informed consent was obtained from all participants in the survey. The KNHANES was approved by the Institutional Review Board of KCDC (2010-02CON-21-C).

A total of 8,958 participants completed the survey through the mobile health examination units. First, we excluded 7,268 subjects according to the following exclusion criteria: age <19 years (n = 2,218), absence of laboratory data (n = 4,806), and absence of alcohol intake history (n = 244). Of the remaining 1690 subjects, we additionally excluded 324 patients with hepatitis B (n = 57), hepatitis C (n = 2), liver cancer (n = 2), and significant alcohol consumption (n = 263). Significant alcohol consumption was defined as alcohol intake >210 g/week in men or >140 g/week in women [14]. A total of 1,366 subjects with no viral hepatitis, liver cancer, and significant alcohol consumption were identified. Of 1,366 subjects, a total of 300 subjects with NAFLD were finally analyzed (Fig 1). NAFLD was defined as NAFLD liver fat score >-0.64 [15].

Fig 1

Flow diagram of enrolled patients.

Abbreviations: KNHANES, Korea National Health and Nutrition Survey; NAFLD, non-alcoholic fatty liver disease.

Clinical variables

The information on alcohol consumption was obtained during the health interview survey. Alcohol consumption was evaluated by asking the subjects about drinking behavior during the month just before the interview. The participants were asked for their average frequency (days per month) of alcoholic beverage consumption and average amount (units of drink/day) of alcoholic beverage ingested on a single occasion. Each unit was equivalent to approximately 10 g of alcohol. Diabetes mellitus was defined as fasting blood glucose ≥ 126mg/dL or treated with anti-diabetic drug.

Blood tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), total cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride, and 25-hydroxyvitamin D (25(OH)D), were conducted after 12 h of fast. The KNHANES was conducted by the KCDC and a variety of health measurements were added to the basic design to meet emerging data needs. All health examination components including blood sample collection have been conducted in the Mobile Examination Centers (MECs) that travel to each survey location. These MECs provide a standardized environment and equipment. Routine biochemical tests, including total cholesterol, triglyceride, glucose, high-density lipoprotein (HDL) cholesterol, LDL cholesterol, ALT, and AST, were performed using the ADVIA 1650 analyzer (Bayer, Pittsburgh, PA, USA). Hepatitis B surface antigen was measured by electrochemiluminescence immunoassay method using the E-170 automated analyzer (Roche, Penzberg, Germany). Serum 25(OH)D levels were measured using a counter (1470 Wizard; Perkin-Elmer, Turku, Finland) with a radioimmunoassay method (Dia-Sorin; Still Water, MN, USA). A trace element tube was used to measure serum Zn levels. Blood samples for measuring zinc level were mixed for 10 min using a roller mixer immediately to avoid the formation of blood clots, and then were refrigerated immediately and transported in cold storage to the Central Testing Institute in Seoul, Korea. All blood samples were analyzed within 24 h after arrival at the Central Testing Institute. Zn level was measured using inductively coupled plasma mass spectrometry (ICP-MS) using PerkinElmer ICP-MS (PerkinElmer, MA, USA). IR was evaluated using Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) [16]. Hepatic fibrosis was assessed using the Fibrosis-4 (FIB-4) index. Significant hepatic fibrosis was defined as FIB-4 index >1.3 [17].

Statistical analysis

The t-test and chi-square test were used in the comparisons of continuous and categorical variables, respectively. Partial correlation analysis between serum Zn level and FIB-4 index was done adjusting potential confounding factors which could affect the relationship. Univariable and multivariable logistic regression analyses were performed to assess the risk factors, including serum Zn level, for significant hepatic fibrosis in patients with NAFLD. Multivariable analysis was done in the following manners. First, we included in the multivariable analysis any variable that was associated with the outcome at a P-value of <0.10, regardless of whether or not the variable was associated with the risk factor. Second, for multivariable logistic regression analysis, the subjects of analysis should have at least ten outcomes for each independent variable in the multivariable model. Third, multivariable analysis was performed using a forward conditional stepwise procedure to avoid multicollinearity. Thus, we included sex, BMI, LDL level, GGT level, diabetes mellitus, and zinc level in the multivariable analysis. We excluded age in the multivariable analysis because the dependent variable (FIB-4) included age. A P-value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS for Window version 18.0 (SPSS Inc., Chicago, IL).

Results

Baseline characteristics of subjects with NAFLD

The baseline characteristics of subjects with NAFLD are presented in Table 1. The mean age of the subjects was 49.5 years. The proportion of men was 65.7% (197/300). The mean body mass index (BMI) was 26.2 kg/m2. The mean AST, ALT, and GGT levels were 27.6 U/L, 33.8 U/L, and 52.0 U/L, respectively. The proportion of patients with diabetes mellitus was 21.3% (64/300). The mean FIB-4 index was 0.99 ± 0.60, and the mean serum Zn level was 139.8 ± 29.9 μg/dL.

Table 1

Baseline characteristics of the subjects with NAFLD.

	Total (n = 300)	Subjects with high zinc level (≥140 μg/dL) (n = 135)	Subjects with low zinc level (<140 μg/dL) (n = 165)	P-value
Age (year)	49.5 ± 14.0	47.7 ± 13.5	51.0 ± 14.3	0.045
Male	197 (65.7%)	98 (59.4%)	99 (73.3%)	0.011
Height (cm)	165.2 ± 9.0	166.7 ± 8.6	164.1 ± 9.2	0.012
Weight (kg)	71.8 ± 11.9	73.0 ± 12.3	70.8 ± 11.5	0.120
BMI (kg/m2)	26.2 ± 3.3	26.2 ± 3.3	26.3 ± 3.3	0.872
Waist circumference (cm)	89.3 ± 8.8	89.8 ± 8.8	89.0 ± 8.8	0.405
Platelet count (x103/mm2)	261.9 ± 68.1	258.8 ± 57.6	264.6 ± 75.7	0.452
AST (U/L)	27.6 ± 20.7	25.5 ± 10.2	29.2 ± 26.2	0.095
ALT (U/L)	33.8 ± 22.2	33.1 ± 17.4	34.4 ± 25.7	0.614
GGT (U/L)	52.0 ± 57.5	57.3 ± 60.6	47.7 ± 54.7	0.148
FBS (mg/dl)	111.3 ± 31.5	108.8 ± 31.0	113.3 ± 31.7	0.226
Total cholesterol (mg/dl)	198.5 ± 41.3	196.8 ± 37.6	199.9 ± 44.2	0.523
LDL cholesterol (mg/dl)	122.1 ± 34.5	120.1 ± 33.7	123.7 ± 35.2	0.261
HDL cholesterol (mg/dl)	41.6 ± 9.5	40.8 ± 9.8	42.2 ± 9.3	0.202
Triglyceride (mg/dl)	203.8 ± 125.4	217.9 ± 149.7	192.3 ± 100.4	0.079
HOMA-IR score	4.2 ± 2.8	4.2 ± 3.4	4.2 ± 3.4	0.941
NAFLD liver fat score	0.72 ± 1.48	0.68 ± 1.43	0.75 ± 1.51	0.663
FIB-4 index	0.99 ± 0.60	0.89 ± 0.45	1.07 ± 0.70	0.008
Zinc level (μg/dL)	139.8 ± 29.9	166.3 ± 21.4	118.2 ± 14.3	<0.001
25(OH)D level (ng/mL)	18.2 ± 6.4	19.3 ± 6.8	17.2 ± 5.9	0.006
Diabetes mellitus	64 (21.3%)	30 (22.2%)	34 (20.6%)	0.734

*Data were represented as mean ± SD or N (%). Abbreviations: S.D., standard deviation; BMI, body mass index; AST, aspartate transaminase; ALT, alanine transaminase; GGT, gamma glutamyl transferase; FBS, fasting blood sugar; LDL, low density lipoprotein; HDL, high density lipoprotein; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4; 25(OH)D, 25-hydroxyvitamin D.

The comparison of clinical characteristics was conducted between subjects with high Zn level (≥140 μg/dL) and low Zn level (<140 μg/dL). Subjects with low Zn level were older than subjects with high Zn level (51.0 vs 47.7 years, p = 0.045). The proportion of men was higher in subjects with low Zn level than in subjects with high Zn level (73.3% vs 59.4%, p = 0.011). There were no differences in HOMA-IR value; NAFLD liver fat score; and presence of diabetes mellitus between the two groups. The serum 25(OH)D level was significantly higher in subjects with high Zn level than in subjects with low Zn level (19.3 vs 17.2 ng/mL, p = 0.006). There was a significant difference in FIB-4 index between the two groups. The FIB-4 index was higher in subjects with low Zn level than in subjects with high Zn level (1.07 vs 0.89, p = 0.008).

Relationship between serum Zn level and hepatic fibrosis in subjects with NAFLD

The relationship between serum Zn level and hepatic fibrosis (FIB-4 index) in subjects with NAFLD are presented in Fig 2. The FIB-4 index significantly increased as the serum Zn level decreased (Pearson correlation coefficient = -0.120, p = 0.038). We analyzed the correlation between serum zinc and FIB-4 index adjusting potential confounding factors. The partial correlation coefficients (r) adjusted for gender, BMI, GGT, fasting glucose level, triglyceride, LDL cholesterol, HDL cholesterol, diabetes mellitus, and vitamin D level between serum zinc level and FIB-4 index is r = -0.177 with p = 0.003. We investigated the difference in FIB-4 index according to serum Zn level (<120, 120–140, 140–160, and ≥160 μg/dL) (Fig 3). The mean FIB-4 index in serum Zn level <120, 120–140, 140–160, and ≥160 μg/dL were 1.06±0.74, 1.08±0.66, 0.96±0.47, and 0.83±0.43, respectively. The FIB-4 index significantly increased as serum Zn level decreased (p = 0.01). There is an inverse relationship between serum Zn level and hepatic fibrosis in NAFLD.

Fig 2

The relationship between serum zinc level and hepatic fibrosis (FIB-4 index) in subjects with NAFLD.

“r” is Partial correlation coefficient adjusting gender, body mass index, gamma glutamyl transferase, fasting glucose level, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, diabetes mellitus, and vitamin D level. Abbreviations: NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4.

Fig 3

Hepatic fibrosis (FIB-4 index) according to serum zinc level in NAFLD.

Abbreviations: NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4.

Risk factors for significant hepatic fibrosis in subjects with NAFLD

The risk factors for significant hepatic fibrosis in subjects with NAFLD are shown in Table 2. Significant liver fibrosis (FIB-4 index ≥1.3) was observed in 62 patients (21%). The univariable analysis indicated that significant fibrosis in patients with NAFLD was associated with age ≥50 years (odds ratio [OR], 12.23; 95% confidence interval [CI], 5.07–29.49; p<0.001), male sex (OR, 2.05; 95% CI, 1.07–3.93; p = 0.031), serum LDL level ≥130 mg/dL (OR, 0.51; 95% CI, 0.28–0.92; p = 0.025), serum Zn level <140 μg/dL (OR, 1.80; 95% CI, 1.00–3.22; p = 0.050), and diabetes mellitus (OR, 2.83; 95% CI, 1.53–5.24; p = 0.001). The multivariable analysis was done with the forward conditional stepwise method and by six variables (sex, BMI, LDL cholesterol, GGT, diabetes mellitus, and serum zinc level) which were selected by the univariable analysis. The multivariable analysis revealed that the risk factors for significant hepatic fibrosis in subjects with NAFLD were diabetes mellitus (OR, 3.25; 95% CI, 1.71–6.19; p<0.001), male sex (OR, 2.59; 95% CI, 1.31–5.12; p = 0.006), and serum Zn level <140 μg/dL (OR, 2.14; 95% CI, 1.16–3.94; p = 0.015).

Table 2

Risk factors for significant hepatic fibrosis in subjects with NAFLD.

	Univariable OR (95% CI)	p-value	Multivariable OR (95% CI)	p-value
Age
<50 years	1
≥50 years	12.23 (5.07–29.49)	<0.001
Sex
Female	1		1
Male	2.05 (1.07–3.93)	0.031	2.59 (1.31–5.12)	0.006
BMI
<27 kg/m2	1
≥27 kg/m2	0.47 (0.25–0.090)	0.023
Waist circumference
<90 cm (male) / <85 cm (female)	1
≥90 cm (male) / ≥85 cm (female)	1.01 (0.58–1.77)	0.976
Serum LDL level
<130 mg/dL	1
≥130 mg/dL	0.51 (0.28–0.92)	0.025
Serum HDL level
≥40 mg/dL (male) / ≥50 mg/dL (female)	1
<40 mg/dL(male) / <50 mg/dL (female)	0.99 (0.54–1.79)	0.961
Serum triglyceride level
<250 mg/dL	1
≥250 mg/dL	0.84 (0.44–1.57)	0.576
Serum ALT level
<40 U/L	1
≥40 U/L	1.06 (0.56–2.00)	0.869
Serum GGT level
<60 U/L	1
≥60 U/L	1.79 (0.97–3.32)	0.064
HOMA-IR level
<4.2	1
≥4.2	0.69 (0.37–1.29)	0.244
Serum zinc level
≥140 μg/dL	1		1
<140 μg/dL	1.80 (1.00–3.22)	0.050	2.14 (1.16–3.94)	0.015
Serum 25(OH)D level
≥20 μg/dL	1
<20 μg/dL	0.73 (0.41–1.30)	0.284
Diabetes mellitus
Absence	1		1
Presence	2.83 (1.53–5.24)	0.001	3.25 (1.71–6.19)	<0.001

*significant hepatic fibrosis was defined as FIB-4 (fibrosis-4) level was ≥1.3. Abbreviations: BMI, body mass index; ALT, alanine transaminase; GGT, gamma glutamyl transferase; FBS, fasting blood sugar; LDL, low density lipoprotein; HDL, high density lipoprotein; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4; 25(OH)D, 25-hydroxyvitamin D.

Discussion

The present study demonstrates that there is a significant inverse relationship between serum Zn level and liver fibrosis represented by FIB-4 index in patients with NAFLD. Moreover, a serum Zn level <140 μg/dL is an independent risk factor for significant liver fibrosis (FIB-4 index ≥1.3) combined with diabetes and male sex.

Zn, a trace element of a constitution of metabolic, anti-inflammatory, and antioxidant enzymes, can have distorted metabolism in chronic liver disease [18]. Previous studies showed that patients with chronic active hepatitis, cirrhosis, and liver cancer have significantly decreased serum Zn levels [19]. Zn deficiency was shown in patients with chronic hepatitis C, and Zn level was improved by treatment with interferon [20, 21]. Thus, Zn supplementation in patients with chronic hepatitis C and liver cirrhosis improved liver function and long-term outcome, such as lower cumulative incidence of liver cancer. With the same aspect, poor survival in chronic viral patients with early HCC was significantly associated with Zn deficiency as well as incomplete infection control of the hepatitis virus [22]. The risk of esophageal variceal bleeding, the fatal complication of decompensated cirrhosis, was also correlated with the decreased level of Zn in patients with chronic viral hepatitis [6]. Thus, Zn levels are significantly associated with disease severity and prognosis in patients with chronic viral hepatitis. Zn deficiency/altered metabolism is also observed in alcoholic liver disease. Ethanol consumption leads to increased Zn excretion in the urine and decreased Zn absorption in the intestine. Chronic ethanol exposure caused a decrease in hepatic Zn level and metallothionein, the protein with substantial binding site of Zn for its function. Metallothionein containing Zn has a protective effect on alcohol-induced oxidative liver injury [23]. In a mouse model, metallothionein overexpression displayed pathological lipid peroxidation, and protein oxidation was suppressed [8]. Moreover, Zn supplementation prevents ethanol-induced liver injury and hepatic apoptosis to inhibit oxidative stress and alcohol-induced endotoxemia. In a rat model with carbon tetrachloride-induced cirrhosis, the beneficial effect of Zn on liver cirrhosis also was observed. Zn supplementation induced a reduction in the degree of liver injury and normalization of lipid peroxidation [24].

Previous studies were focused on the effect of Zn on viral hepatitis and alcoholic liver disease. Data on the relationship of Zn level and NAFLD are limited. In the present study, we evaluated the effect of Zn level on NAFLD, except with significant alcohol consumption based on drinking frequency and amount of alcohol intake. NAFLD has a multifactorial pathophysiology, including type 2 diabetes mellitus, dyslipidemia, and obesity. Moreover, liver is a key organ in the systemic metabolism in the development of IR and type 2 diabetes mellitus. They shared the same physiology for hepatic fat accumulation, alteration of energy metabolism, and inflammatory signals [25]. Zn is also essential in the synthesis, secretion, and storage of insulin. Thus, Zn depletion induced endoplasmic reticulum stress and cellular stress such as in chronic inflammation. Finally, it induces the development of IR and type 2 diabetes mellitus. The beneficial effects of Zn supplement on IR, glucose, and lipid profile were well reported in patients with metabolic disorders [26, 27].

Thus, we make a postulation that the alteration in Zn level was also related to liver function in patients with NAFLD, like other etiologies of chronic liver disease especially due to physiologic relationship between NAFLD and diabetes mellitus. In our study, we found that Zn level and severity of liver fibrosis (represented by FIB-4 index) had an inverse correlation, and a decreased Zn level is an independent risk factor for significant liver fibrosis in patients with NAFLD. The severity of hepatic fibrosis is a crucial risk factor in the prognosis of NAFLD in terms of the development of liver cirrhosis and liver cancer [1, 28]. Zn deficiency is common in patients with liver cirrhosis and associated with the severity of liver cirrhosis [29]. The findings of this study indicate that Zn is related to liver fibrosis in patients with NAFLD. In the rat model of NAFLD, Mousavi et al. showed that Zn and selenium cosupplementation reduced hepatic lipid peroxidation and angiogenesis marker [30]. Asprouli et al. showed that lower serum Zn levels were associated with higher severity of NAFLD assessed by ultrasonography in 189 patients while serum cesium levels showed a positive association of the severity of NAFLD [31]. Kosari et al. reported that serum Zn level was significantly lower in moderate and severe lobular hepatic inflammation than in mild lobular hepatic inflammation in patients with NASH although enrolled patients were younger (mean age: 36 years) than other studies and the study excluded cirrhotic patients [32]. Takanori et al. showed that the progression of fibrosis, but not the severity of hepatic inflammation, is associated with lower levels of serum Zn in patients with biopsy-proven NAFLD [12]. There are some differences between studies about race, geography and dietary habits which affects to amount of Zn intake. However, these studies showed a similar tendency in terms of the relationship between low Zn level and the progression of hepatic inflammation in patients with NAFLD. The present study was conducted for reliable and representative participants (KNHANES) and used the FIB-4 index which is objective and well-studied for a noninvasive estimate of liver fibrosis. These findings revealed that Zn metabolism is closely associated with the progression of chronic liver disease such as viral hepatitis, alcoholic liver disease, and even NAFLD.

This study has several limitations. First, this study did not consider the histologic findings of hepatic steatosis and fibrosis in patients with NAFLD. We assessed hepatic steatosis and fibrosis using NAFLD liver fat score and FIB-4 index. The gold standard method for the diagnosis of NAFLD and liver fibrosis is the evaluation of histological findings by liver biopsy. However, it is not widely used because of the invasiveness and the cost. This study was conducted based on a nationally representative survey complex, stratified, multistage, and probability cluster sampling of the noninstitutionalized population (the KNHANES 2010). A total of 8,958 participants completed the survey. Therefore, it is hard to check liver biopsy for the diagnosis of NAFLD and hepatic fibrosis in these many participants. In this study, we evaluated NAFLD (NAFLD liver fat score) and hepatic fibrosis (FIB-4) using commonly used blood tests. The diagnostic accuracy of NAFLD liver fat score for NAFLD is that AUROC was 0.86–0.87 with sensitivity 86% and specificity 71% [33]. The diagnostic accuracy of the FIB-4 index for advanced fibrosis in histology is high in patients with NAFLD (mean value of area under curve, 0.80; 95% CI, 0.77–0.84) [32]. In this study, we defined the cut-off point of FIB-4 for liver fibrosis as 1.3. The reason is as follows. A meta-analysis reported that the cut-off point of FIB-4 for advanced fibrosis in NAFLD was 2.67 or 3.25 while another meta-analysis showed that the cut-off point was 1.3 [34, 35]. The cut-off point of 2.67 had an advantage in terms of positive predictive value for identifying advanced fibrosis in NAFLD while that of 1.3 had a 90% negative predictive value [36]. In the present study, the number of patients with FIB-4 >2.67 was 8 (3%) while 62 patients (21%) had the level of FIB-4 >1.3. It was difficult to perform the univariable and multivariable logistic regression analysis using the FIB-4 cut-off with 2.67. Thus, we defined the cut-off point of FIB-4 as 1.3 in this study [35]. The survey of this study did not include other noninvasive studies such as ultrasonography, transient elastography, and magnetic resonance elastography. If the study had been able to integrate non-invasive imaging techniques for the evaluation of fibrosis, the diagnostic accuracy of hepatic fibrosis would be improved because the diagnostic accuracy of FIB-4 is a little low compared to that of transient elastography or magnetic elastrography (area under the receiver operating characteristics for significant liver fibrosis: FIB-4 0.75, transient elastography 0.83, and magnetic resonance elastography 0.88) [34]. We also calculated non-invasive fibrosis markers besides FIB-4 index: (i) AST to Platelet Ratio (ARPI) score = 100 × (AST / upper limit of normal) / platelet count (×109/L) [37]; (ii) BARD score = (BMI ≥ 28 = 1 point, AST to ALT ratio ≥ 0.8 = 2 points, diabetes = 1 point), scale 0–4 [38]. However, NAFLD fibrosis score could not be calculated because our database did not provide the information about serum albumin level. The mean level of APRI score was 0.29 while the median value of BARD score was 2. The relationship between serum zinc level and APRI score or BARD score was not stronger than that between zinc and FIB-4 index (correlation coefficients r = -0.191, p = 0.117 in ARPI score; r = -0.120, p = 0.039 in BARD score). Second, this study did not investigate the interaction between Zn and other trace elements, vitamins, and hormones, such as copper, iron, selenium, vitamin A, and testosterone. We evaluated the positive correlation between serum Zn level and vitamin D level (correlation coefficient = 0.225, p<0.001). However, there was no significant relationship between the FIB-4 index and serum vitamin D level (correlation coefficient = 0.077, p = 0.181). Vitamin D level was not a risk factor for significant liver fibrosis in this study. Third, we were unable to determine the oral intake of Zn and serum albumin level which could affected to the lower Zn in NAFLD because the data from the KNHANES did not provide information about Zn intake and albumin. We assumed that the patients with relatively low Zn levels were more likely to have NAFLD or NASH. However, this study could not evaluate the mechanism of lower zinc level in patients with NAFLD affected by Zn intake or albumin level. Zinc-rich foods are meat, shellfish, beans, seeds, nuts, dairy foods, eggs, and whole grains. Although the KNHANES provided information about the intake of these foods, it did not provide information about oral Zn intake. Previous other studies reported that oral Zn intake was decreased in patients with NAFLD. Zolfaghari et al. showed that oral Zn intake in patients with NAFLD was significantly lower than that in normal healthy controls [39]. Toshimitsu et al. revealed that NASH patients had lower Zn intake compared to patients with fatty liver (simple steatosis) [40]. Finally, the study could not investigate the effect of Zn supplementation on the regression of liver fibrosis in NAFLD because the study was conducted based on observational studies.

Conclusions

This study observed an inverse relationship between serum Zn level and FIB-4 index in patients with NAFLD. Low levels of serum Zn were an independent risk factor for significant hepatic fibrosis in patients with NAFLD. Zn might play a fundamental role in the pathophysiology of hepatic fibrosis in NAFLD.

28 Jul 2020

PONE-D-20-13707

Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease

PLOS ONE

Dear Dr. Sohn,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 11 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Peter Starkel, M.D., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating in your manuscript text "Written informed consent was obtained from all participants in the survey". Please also include this in your ethics statement.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Additional Editor Comments (if provided):

The authors must address all remarks carefully and provide the additional analyses (statititics, regression analysis etc.) requested by the reviewers. In particular, attention should be given to the interpretation of the results with regard to the cut-offs chosen and the very weak correlation with zinc levels.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Kim MC have described the manuscript entitled “Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease”. The authors demonstrated the relationship between serum Zn level and hepatic fibrosis in NAFLD. Zn is reported to be important nutritional factor related to liver fibrosis and various types of carcinogenesis, including HCC. However, this article has some critical problems and limitations. Specific comments are given below.

1. Regarding serum Zn levels in NAFLD, recent reports have already shown the relationship between Zinc and NAFLD, and prognosis in biopsy-proven NAFLD cohort (EJGH2019, Nutrition and Cancer 2019). In this report, NAFLD participants were diagnosed with NAFLD liver fat score, not biopsy. And also, they only used Fib4 index for evaluating liver fibrosis. Liver biopsy is the gold standard for diagnosing NAFLD and assessing liver fibrosis, therefore, this study has a lack of novelty for publication.

2. The authors have set the cut off value of Fib4 index as 1.3 for evaluating significant fibrosis. As the authors have described as limitation in Discussion part, Fib4 index of 1.3 is known as the cut off point for rule out the patients with mild/no fibrosis, and the proportion of the patients with Fib4 of 2.67 or more, which is focused more for the cut off with positive predictive value, was only 8%. Fibrosis is well known as the strong factor for predicting prognosis for NAFLD patients, so the cohort in this study was not good enough, because the number of patients with significant fibrosis, which reach the level to affect the prognosis might be small, and this results less information for clinical practice.

3. How did author set the cut-off value of serum zinc level? If the authors emphasize the importance of Zn level in NAFLD, they should use the definition on Zn deficiency. Zinc deficiency is defined as serum Zn level <70 μg/dL based on previous report (Harrison’s Principles of Internal Medicine 2015). Otherwise, clinical impact should be small.

4. Following the above, mean value of serum Zn in whole participants was 139.8 μg/dL. This value is within normal limits or higher, and it is expected that the majority of participants in this study has normal liver without any hepatic inflammation and fibrosis.

5. The mechanism to induce lower Zn levels in NAFLD in this study was unclear. Hypoalbuminemia is one of the most important factors that can lead to Zn deficiency because Zn mainly binds to albumin during transportation in the blood. Additionally, hypoalbuminemia is a common metabolic disorder induced by liver cirrhosis. The authors need to add the information of serum albumin in Table1, and put albumin in logistic regression analysis.

6. Circadian variation of Zn levels has been recognized well. Were the blood samples of participants in this study collected under the same conditions, such as in the morning with a fasting state?

7. To conduct the linear regression analysis, the authors should weigh the R-values more compared with P-values. The authors showed the significant relationship in P-value (p=0.038) with Pearson correlation test, but coefficient value was -0.120. This result indicated very weak correlation on these two factors, And the statistical interpretation is not strong.

Reviewer #2: Data from a large cohort.

Limitations were partially described by the authors.

Remarks:

-only use of non invasive marker FIB4? The cutt-off used in this trial was 1.3 for significant fibrosis. Is age also taken into account?

-are there any data of echography or fibroscan in the patient group with NAFLD?

-is there any recommendation about Zinc intake of supplementation that can be given to patients with NAFLD?

Reviewer #3: In this study, the authors show that low blood zinc level is associated with higher FIB-4 score in a population of NAFLD-suspected patients (based on NAFLD liver fat score).

Major comments:

- The authors mention in the discussion that “data on NAFLD are limited” (page 12) without giving any reference. However, another study is available with the same observation based on histological results (Takanori et al. PMID 31688305), accepted one year ago. The authors should add this reference and discuss it.

- The criteria used for both NAFLD diagnosis and fibrosis are based on simple non-invasive scores. This should be clearly mentioned in the discussion. Other better non-invasive diagnostic tools exist such as transient elastography or MRI (for the evaluation of both steatosis and fibrosis).

- The Pearson correlation (between FIB-4 and Zn) is weak (-0.120). There is no figure with the graph. The authors should add it as a scatterplot, because it is the main message of the paper.

- The reason why the authors included only 6 variables in the multivariate analysis is not clear. It is true that looking for a correlation with the FIB-4 score exclude the evaluation of age, ALT, AST which are usual parameters associated with fibrosis (probably better than zinc levels). Furthermore, BMI (mentioned as included in the methods but no result available) or waist circumference should probably be included.

Minor comments:

- Numerous similar data are presented in the text and in the Table 1 (redundant information).

- The HOMA-IR is the same in the two groups (high or low zinc level). Is the HOMA-IR available in all patients?

- What is the definition of diabetes mellitus? treatment for hyperglycemia? Blood glucose > 126mg/dL?

- Was the HOMA-IR calculated/available also in treated diabetic patients? Under treatment?

- Data are available on the daily micronutrients intake in control, NAFLD and NASH patients (for example Musso et al. Hepatology 2003). Are there data on zinc intake?

- Another study with histology (Kosari et al.) is presented in the references. Histological results are also available in this study. However, in this study, there was no correlation between fibrosis and zinc levels but with portal inflammation. This should be discussed.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

21 Aug 2020

Dear Peter Starkel

We answered the reviewers’ comments point by point and revised the manuscript to carefully address all the concerns raised by the handling editor and reviewers. We attached the file 'Response to Reviewers'. We thank to the editor and the reviewers for the informative reviews and now hope that the revised manuscript is now suitable for the publication in the “Plos One”.

With best wishes.

Yours sincerely.

Won Sohn, M.D., Ph.D.

Submitted filename: Respone to reviewers.docx

Click here for additional data file.

22 Sep 2020

Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease

PONE-D-20-13707R1

Dear Dr. Sohn,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Peter Starkel, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The revised paper has been improved and all major points have been addressed.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: The authors answered the questions well and improved their manuscript.

The limitations are clearly stated. The reference to the similar study is now mentioned.

An added sentence can be improved: page 15, line 22 " If the study could check the noninvasive imaging studies, the ..." ? This can be rewritten in this way: "If the study had been able to integrate non-invasive imaging techniques for the evaluation of fibrosis ..."

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

12 Oct 2020

PONE-D-20-13707R1

Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease

Dear Dr. Sohn:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Peter Starkel

Academic Editor

PLOS ONE